{
    "Clinical Trial ID": "NCT01302379",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Metformin + Lifestyle Intervention",
        "  Metformin: Week 1: 500 mg at dinner time Weeks 2-4: 1000 mg at dinner time Weeks 5+: 500 mg in morning; 1000 mg at dinner time",
        "  Lifestyle intervention: Telephone-based lifestyle intervention (dietary change and physical activity) for weight loss.",
        "INTERVENTION 2: ",
        "  Placebo + Lifestyle Intervention",
        "  Placebo: Week 1: 1 pill at dinner time Weeks 2-4: 2 pills at dinner time Weeks 5+: 1 pill in morning; 2 pills at dinner time",
        "  Lifestyle intervention: Telephone-based lifestyle intervention (dietary change and physical activity) for weight loss."
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  BMI at least 25.0 kg/m2",
        "  Diagnosed with Stage I, II, or III breast cancer within past 5 years",
        "  Treatment with total mastectomy or breast-sparing surgical removal of cancer with clear macroscopic margins, and axillary dissection, followed by adjuvant breast radiation",
        "  Not scheduled for or currently undergoing chemotherapy",
        "  Accessible geographically and by telephone",
        "  Able to communicate dietary and physical activity data via telephone",
        "  If taking statins, tamoxifen, or aromatase inhibitors; able and willing to remain on treatment for 6-month study period",
        "  Post-menopausal at diagnosis",
        "Exclusion Criteria:",
        "  Preliminary bloodwork outside of specified ranges",
        "  Evidence of renal insufficiency, liver disease, or congestive heart failure",
        "  Currently taking corticosteroid pills or steroid hormone therapy (including vaginal estrogen creams)",
        "  Recent initiation (< 3 months ago) of thiazides or \u03b2-blockers",
        "  Taking insulin or other antidiabetic drug",
        "  Other primary or recurrent invasive cancer in past 10 years",
        "  Unable to commit to study requirements"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Insulin",
        "  Insulin measured as percent change from baseline",
        "  Time frame: change from baseline to 6 months",
        "Results 1: ",
        "  Arm/Group Title: Metformin + Lifestyle Intervention",
        "  Arm/Group Description: Metformin: Week 1: 500 mg at dinner time Weeks 2-4: 1000 mg at dinner time Weeks 5+: 500 mg in morning; 1000 mg at dinner time",
        "  Lifestyle intervention: Telephone-based lifestyle intervention (dietary change and physical activity) for weight loss.",
        "  Overall Number of Participants Analyzed: 83",
        "  Least Squares Mean (95% Confidence Interval)",
        "  Unit of Measure: percent change from baseline  -21.8        (-29.7 to -13.0)",
        "Results 2: ",
        "  Arm/Group Title: Placebo + Lifestyle Intervention",
        "  Arm/Group Description: Placebo: Week 1: 1 pill at dinner time Weeks 2-4: 2 pills at dinner time Weeks 5+: 1 pill in morning; 2 pills at dinner time",
        "  Lifestyle intervention: Telephone-based lifestyle intervention (dietary change and physical activity) for weight loss.",
        "  Overall Number of Participants Analyzed: 83",
        "  Least Squares Mean (95% Confidence Interval)",
        "  Unit of Measure: percent change from baseline  -17.7        (-25.9 to -8.6)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 5/333 (1.50%)",
        "  transient ischemic attack1/333 (0.30%)",
        "  Injury due to fall1/333 (0.30%)",
        "  Abdominal pain1/333 (0.30%)",
        "  slurred speach1/333 (0.30%)",
        "Adverse Events 2:",
        "  Total: 5/333 (1.50%)",
        "  transient ischemic attack1/333 (0.30%)",
        "  Injury due to fall1/333 (0.30%)",
        "  Abdominal pain1/333 (0.30%)",
        "  slurred speach1/333 (0.30%)"
    ]
}